Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
08:54am, Wednesday, 18'th Sep 2024
- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash
GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.
11:46am, Friday, 09'th Aug 2024
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
10:11am, Friday, 09'th Aug 2024
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
08:40am, Thursday, 08'th Aug 2024
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
06:30am, Thursday, 08'th Aug 2024
- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (tr
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
10:24am, Wednesday, 07'th Aug 2024
MILWAUKEE , Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos. Click h
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
08:30am, Wednesday, 07'th Aug 2024
G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstandin
Pharmacosmos Group to Acquire G1 Therapeutics
06:29am, Wednesday, 07'th Aug 2024
- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myelo
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:50pm, Thursday, 01'st Aug 2024
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
11:15am, Thursday, 25'th Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
02:00pm, Monday, 15'th Jul 2024
While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
06:40am, Wednesday, 10'th Jul 2024
Biotechnology stocks can be thrilling and profitable when you're on the winning side of a trade. G1 Therapeutics' (NASDAQ: GTHX ) started hot, but then the bottom fell out after an unfortunate announc
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
08:00am, Monday, 01'st Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
10:00am, Monday, 24'th Jun 2024
G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows poten
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
09:40am, Monday, 24'th Jun 2024
Shares of G1 Therapeutics Inc GTHX are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaci
